DNMT3B Primary Antibody
|Aliases||ICF; ICF1; M.HsaIIIB|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human DNMT3B (AA: 1-150) expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Figure 1: Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Figure 2:Western blot analysis using DNMT3B mAb against human DNMT3B (AA: 1-150) recombinant protein. (Expected MW is 42.6 kDa)
Figure 3:Western blot analysis using DNMT3B mAb against HEK293 (1) and DNMT3B (AA: 1-150)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4:Flow cytometric analysis of K562 cells using DNMT3B mouse mAb (green) and negative control (red).
Figure 5:Immunohistochemical analysis of paraffin-embedded colon cancer tissues using DNMT3B mouse mAb with DAB staining.
Figure 6:Immunohistochemical analysis of paraffin-embedded esophageal cancer tissues using DNMT3B mouse mAb with DAB staining.
|Description||CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined.|
|References (references)||1.PLoS One. 2013 Jul 19;8(7):e69486. |
2.Blood Coagul Fibrinolysis. 2012 Oct;23(7):636-9.